Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
28 févr. 2025 09h08 HE
|
Alumis Inc.
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
27 févr. 2025 16h15 HE
|
Alumis Inc.
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
Alumis Strengthens Leadership Team with Key Appointments
28 janv. 2025 08h00 HE
|
Alumis Inc.
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
14 janv. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
19 déc. 2024 08h00 HE
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
14 nov. 2024 16h05 HE
|
Alumis Inc.
Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
13 nov. 2024 16h05 HE
|
Alumis Inc.
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
27 sept. 2024 09h00 HE
|
Alumis Inc.
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis
Alumis to Participate in Upcoming September Investor Conferences
03 sept. 2024 16h29 HE
|
Alumis Inc.
Alumis will be participating in several investor conferences in September
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
13 août 2024 16h05 HE
|
Alumis Inc.
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...